The Chinese name of Pirtobrutinib is Pitobrutinib or Pitobrutinib. This article will help you understand!

In 2024, Pirtobrutinib will be officially launched in China, and its Chinese name will be "Pitobrutinib" instead of "Pitobrutinib" as used in some previous data. Pitobrutinib is a new generation of oral Bruton's tyrosine kinase (BTK) inhibitor developed by Eli Lilly Company, and its trade name is "Jaypirca". Its advent marks the world's first and currently only approved non-covalent reversible BTK inhibitor that has officially entered the clinical application stage. It is especially suitable for patients with relapsed or refractory mantle cell lymphoma (MCL), especially those who have received at least two systemic treatments (including covalent BTK inhibitors) but with poor efficacy.

The clinical significance of pitubrutinib is very important. Although traditional covalent BTK inhibitors such as ibrutinib have shown good efficacy in a variety of B-cell malignancies, some patients will develop drug resistance due to BTK gene mutations (such as C481S), resulting in reduced efficacy or even disease progression. Pitobrutinib can effectively overcome this type of resistance mechanism by virtue of its non-covalent binding and reversible inhibition mechanism. In clinical trials, it has been shown that patients who were resistant to previous BTK therapy still have a good response rate, making it an important supplement for the treatment of lymphomas such as MCL.

In the National Comprehensive Cancer Network (NCCN) guidelines, pitubrutinib is clearly recommended for specific MCL patients and is one of the first-line subsequent treatment options currently supported by international authoritative guidelines. However, it should be noted that as of now, pitubrutinib has not been included in China's national medical insurance directory, so its treatment cost is still high. For some patients with a heavy financial burden, it may be necessary to seek affordable treatment pathways through charity assistance, commercial insurance, or clinical trial channels.

In general, the launch of Pitobrutinib provides a more forward-looking option for domestic lymphoma treatment, fills the treatment gap for BTK-resistant patients, and is another important breakthrough in precision medicine and personalized treatment.

Reference materials:https://go.drugbank.com/drugs/DB17472